SMAD3 and hepatocellular carcinoma: The results showed that genetic editing of TERT promoter mutation into the wild‐type nucleotide significantly decreased the protein levels of Smad3 (Figure 6H and I) but had little effects on transcriptional levels (Figure S5D), and induced resistance to the effects of PLK1 inhibitor on TERT mutant HCC cells (Figures 3D–H and S2D–G).